From: "Clayton Finley" <Chelsea327@yahoo.com>
To: <paliourg@iit.demokritos.gr>
Subject: Fw: [8] Emerging Stock
Date: Mon, 10 May 2004 06:28:57 +0300
MIME-Version: 1.0
Content-Type: text/html;
	charset="iso-8859-7"
Content-Transfer-Encoding: quoted-printable
X-Priority: 3
X-MSMail-Priority: Normal
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.2527

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<META HTTP-EQUIV=3D"Content-Type" CONTENT=3D"text/html; =
charset=3Diso-8859-7">
<META NAME=3D"Generator" CONTENT=3D"MS Exchange Server version =
6.5.7036.0">
<TITLE>Fw: [8] Emerging Stock</TITLE>
</HEAD>
<BODY>
<!-- Converted from text/plain format -->

<P><FONT SIZE=3D2>Stock Finder Newsletter wants to inform aggressive =
investors of a company that we feel is extremely undervalued and poised =
for growth.<BR>
<BR>
12 to 20 Plus Inc&nbsp; (OTCBB:TTTP)<BR>
Fiscal Year End: Dec 31<BR>
52 Week High: $.25<BR>
Shares Outstanding : 30 Million<BR>
Shares in the Public Float: 4 Million<BR>
<BR>
TARGET PRICE IN NEXT 3-5 DAYS: $0.75 - 0.80<BR>
TARGET PRICE IN NEXT 10 DAYS: $0.92<BR>
<BR>
The Company<BR>
12 to 20 Plus, Inc. (OTCBB: TTTP) is a late stage development company =
that produces and<BR>
markets (through its Neurochemical Research Group division) highly =
effective<BR>
condition-specific supplements, often referred to as =
neutraceuticals.<BR>
<BR>
The products, manufactured by FDA-approved labs, contain a sophisticated =
combination of<BR>
extensively researched nutritional elements and do not contain herbs. =
Retail sales in the<BR>
explosive dietary supplement market are expected to hit $40 billion by =
the year 2007,<BR>
according to Frost &amp; Sullivan reports.<BR>
Marketing research, product development, Beta testing and various =
mergers and acquisitions<BR>
in 2003, has now positioned 12 to 20 Plus (TTTP) to roll out its full =
product line<BR>
consisting of 7 products of which they have their own proprietary =
formula, into the<BR>
multi-billion dollar Over the Counter (OTC) market. 12 To 20 Plus is =
ready to capitalize<BR>
on its exceptional product line.<BR>
Key Facts about 12 to 20 Plus Inc<BR>
<BR>
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; They have introduced 9 products to =
the market that the company owns the proprietary<BR>
&nbsp;rights to,&nbsp; products that have been produced in FDA approved =
labs.<BR>
<BR>
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One of their products Anaplex =
(antidepressant) is currently being sold and distributed<BR>
&nbsp;in Longs Drug Stores, one of America&#146;s leading drug stores =
with over 400 stores<BR>
<BR>
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The company is negotiating deals =
with two major distributors in Europe for their<BR>
healthcare products.<BR>
<BR>
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; They are currently in process of =
attempting to market one their newest products a<BR>
&nbsp;revolutionary re-hydration product to the U.S Military and to =
allied forces overseas.<BR>
<BR>
<BR>
The Industry<BR>
The neutraceutical sector has experienced some great growth over the =
past five years,<BR>
being capped off in 2002 when revenues for the global nutrition markets =
hit $160 billion.<BR>
United States took responsibility for about 1/3 of that, with $56.5 =
billion, 18.5 coming<BR>
from the nutrition markets, $19.8 from functional foods, and $4.4 =
billion from personal<BR>
care products. It&#146;s safe to say that globally we are looking for =
new ways to live<BR>
healthier and longer lives, and that pharmaceutical remedies could =
quickly be a thing of<BR>
the past.<BR>
<BR>
It&#146;s estimated that 95% of medical doctors` practices entail =
writing pharmaceutical<BR>
prescriptions and that 50% of these prescriptions are to treat the side =
effects of<BR>
medications being utilized to treat the specific ailment.<BR>
People are no longer neglecting the facts that what they are putting =
into their bodies,<BR>
may not be good for them, medicinal foods or &quot;nutritionally high =
powered foods&quot; have been<BR>
in the natural products industry for a long time and through emerging =
scientific research<BR>
the public interest has the reached the mainstream.<BR>
<BR>
It seems as though everywhere you look these days the talk is on dieting =
whether it be the<BR>
low carbohydrate/high protein Atkins diet, The Zone diet, or any of the =
other millions of<BR>
options we have, the world is concerned with weight. According to the =
American Obesity<BR>
Association, of adults over the age of 20 in the United States 127 =
million are overweight,<BR>
60 million are obese, and 9 million are severely obese. Obesity =
increases the risk of<BR>
illness from 30 serious medical conditions. This fact is forcing many of =
the snack food<BR>
and soft drink companies to come up with new healthier products that =
meet the taste<BR>
standards of today&#146;s consumers.<BR>
<BR>
Comparable companies in this Sector<BR>
<BR>
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; USANA Health Sciences Inc =
(Nasdaq:USNA)&nbsp; current price $27.39<BR>
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nutraceutical International Corp =
(Nasdaq:NUTR) current price $25.97<BR>
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vital Living Inc (OTCBB:VTLV) =
current price $.68<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
Disclaimer:<BR>
<BR>
This contains forward-looking statements within the meaning of The =
Private Securities Litigation Reform Act of 1995. These statements may =
be identified by such terms as expect&quot;, &quot;believe&quot;, =
&quot;may&quot;, &quot;will&quot;, =
&quot;explode&quot;,&quot;move&quot;,&quot;undervalued&quot; and =
&quot;intend&quot; or similar terms. The information in the above =
statement could not be 100% accurate and the newsletter is not =
responsible for this. We are NOT a registered investment advisor or a =
broker dealer. This is NOT an offer to buy or sell securities. No =
recommendation that the securities of the companies profiled should be =
purchased, sold or held by individuals or entities that learn of the =
profiled companies. This newsletter was paid $3000 in cash by =
third--party to publish this report.Investing in companies profiled is =
high-risk and use of this information is for reading purposes only. If =
anyone decides to act as an investor, then it will be that investor's =
sole risk. Investors are advised NOT to invest without the proper =
advertisement from an attorney or a registered financial broker. Do not =
rely solely on the information presented,do additional independent =
research to form your own opinion and decision regarding investing in =
the profiled companies. Be advised that the purchase of such high-risk =
securities may result in the loss of your entire investment. Void where =
prohibited. The owners of this publication or their partners may already =
own free trading shares in TTTP and may immediately sell all or a&nbsp; =
the time this date stated and are subject to change without notice.<BR>
<BR>
<BR>
<BR>
</FONT>
</P>

</BODY>
</HTML>
